- Home
- GBTG vs MRUS Comparison
GBTG vs MRUS Comparison
Compare GBTG & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBTG
- MRUS
- Stock Information
- Founded
- GBTG 2014
- MRUS 2003
- Country
- GBTG United States
- MRUS Netherlands
- Employees
- GBTG N/A
- MRUS N/A
- Industry
- GBTG Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- GBTG Technology
- MRUS Health Care
- Exchange
- GBTG Nasdaq
- MRUS Nasdaq
- Market Cap
- GBTG 2.9B
- MRUS 2.7B
- IPO Year
- GBTG N/A
- MRUS 2016
- Fundamental
- Price
- GBTG $6.26
- MRUS $56.07
- Analyst Decision
- GBTG Strong Buy
- MRUS Strong Buy
- Analyst Count
- GBTG 4
- MRUS 15
- Target Price
- GBTG $9.63
- MRUS $88.87
- AVG Volume (30 Days)
- GBTG 1.1M
- MRUS 1.6M
- Earning Date
- GBTG 05-06-2025
- MRUS 05-07-2025
- Dividend Yield
- GBTG N/A
- MRUS N/A
- EPS Growth
- GBTG N/A
- MRUS N/A
- EPS
- GBTG N/A
- MRUS N/A
- Revenue
- GBTG $2,434,000,000.00
- MRUS $54,732,000.00
- Revenue This Year
- GBTG $2.02
- MRUS $39.00
- Revenue Next Year
- GBTG $4.17
- MRUS $7.48
- P/E Ratio
- GBTG N/A
- MRUS N/A
- Revenue Growth
- GBTG 4.82
- MRUS 42.77
- 52 Week Low
- GBTG $5.78
- MRUS $33.19
- 52 Week High
- GBTG $9.60
- MRUS $61.28
- Technical
- Relative Strength Index (RSI)
- GBTG 46.92
- MRUS 66.86
- Support Level
- GBTG $6.15
- MRUS $49.46
- Resistance Level
- GBTG $6.32
- MRUS $56.74
- Average True Range (ATR)
- GBTG 0.15
- MRUS 3.37
- MACD
- GBTG 0.05
- MRUS 1.57
- Stochastic Oscillator
- GBTG 82.86
- MRUS 91.31
About GBTG Global Business Travel Group Inc.
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.